Abstracts tagged "Comorbidity"

Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas¹, Carol J. Etzel², Margaux Crabtree³, Jennie H. Best⁴, Steve Zlotnick⁴ and Joel Kremer⁵, ¹Columbia University, New York, NY, ²Corrona LLC, Waltham, MA, ³Corrona, LLC, Waltham, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…
Abstract Number: 1565 • 2018 ACR/ARHP Annual Meeting
Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Chiara Baldini¹, Francesco Ferro¹, Nicoletta Luciano¹, Emanuele Calabresi¹, Antonella Cecchettini², Marta Mosca¹, Enzo Grossi¹ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²IFC, CNR, Pisa, Italy
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex disorder that may affect any organ and system. In this new era of personalized medicine, a growing…
Abstract Number: 1634 • 2018 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study
Cristina Fernández-Carballido¹, Maria Auxiliadora Martin², María Carmen García-Gómez³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, Rosario García-Vicuña⁷, Celia Erausquin⁸, Francisco J Lopez-Longo⁹, María D Sanchez-Gonzalez¹⁰, Alfonso Corrales¹¹, Estefania Quesda-Masachs¹², Eugenio Chamizo Carmona¹³, Carmen Barbadillo¹⁴, Javier Bachiller¹⁵, Tatiana Cobo-Ibáñez¹⁶, Ana Turrión Nieves¹⁷, Emilio Giner Serret¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay¹¹, ¹Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ⁹Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico, Salamanca, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Rheumatology Division, Hospital Vall Hebrón, Barcelona, Spain, ¹³Rheumatology, Hospital de Mérida, Merida, Spain, ¹⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁵Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁸Rheumatology, H Obispo Polanco, Teruel, Spain, ¹⁹Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain
Background/Purpose: Functional status gets worse with comorbidities regardless of disease activity in patients with rheumatoid arthritis (RA). However, the impact of comorbidities on physical function…
Abstract Number: 1845 • 2018 ACR/ARHP Annual Meeting
Defining and Examining Retention in Care in an Urban Lupus Cohort
Umber Ahmad¹, Ian Chang², Marit Johnson³, Ann Rosenthal³, Amanda Perez⁴ and Christie M. Bartels⁴, ¹Consultant Care (CC111W) - Rheumatology/Medicine, Milwaukee VA Medical Center, Milwaukee, WI, ²Medicine/Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Systemic Lupus Erythematous (SLE) disproportionately impacts black patients and those of low socioeconomic status who experience higher rates of kidney disease and premature mortality.…
Abstract Number: 2236 • 2018 ACR/ARHP Annual Meeting
Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Precise estimates of the comorbidity burden of gout and hyperuricemia are critical as their presence has important implications for the treatment of both gout…
Abstract Number: 1902 • 2017 ACR/ARHP Annual Meeting
A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Jon T. Giles¹, Cheilonda Johnson², Elana J. Bernstein³, Erika Darrah⁴, Felipe Andrade⁵ and Sonye K. Danoff⁶, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Columbia University, New York, NY, ⁴Department of Medicine/Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The pathogenesis and prediction of RA-associated interstitial lung disease (ILD), an extra-articular manifestation with high morbidity and mortality, is poorly understood. We explored the…
Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Cynthia K. Manos^1,2, Rui Xiao³, Timothy G. Brandon¹, Alexis Ogdie⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, ³Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…
Abstract Number: 2388 • 2017 ACR/ARHP Annual Meeting
Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Thorsten Eidner³, Stefan Kleinert⁴, Wolfgang Ochs⁵ and Angela Zink⁶, ¹Epidemiology Unit, German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Univeris, Berlin, Germany, ³Rheumatology/ Osteology, Friedrich-Schiller-University Jena, University Clinic, Jena, Germany, ⁴Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: Osteoporosis, diabetes, hypertension and cardiovascular diseases are the most threatening glucocorticoid (GC)-related comorbidities in rheumatoid arthritis (RA), both from the patients and rheumatologists perspective1.…
Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 1004 • 2017 ACR/ARHP Annual Meeting
Arthritis Impact at the State and County Level — United States, 2015
Kamil E. Barbour¹, Suson Moss², Janet Croft², Jennifer M. Hootman³, Louise Murphy⁴, Kristina Theis², Yan Wang², Hua Lu², Teresa J. Brady¹ and Charles G. Helmick², ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³Centers for Disease Control and Prevention, Kennesaw, GA, ⁴Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Arthritis, a leading cause of disability, affects 54.4 million US adults. By knowing the state and county level arthritis impact, state-level public health professionals…
Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Patrick R. Wood¹, Evan Manning², Joshua Baker³, Grant Cannon⁴, Lisa Davis⁵, Bryant R. England⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Div of Rheumatology, Denver Health, Denver, CO, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…
Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Atul A. Deodhar¹, Kevin Winthrop², Benjamin Chan², Sarah A. R. Siegel², Lisa Pisenti³, Jeffrey Stark³, Robert Y. Suruki⁴, Rhonda L. Bohn⁴, Huifeng Yun⁵, Lang Chen⁵ and Jeffrey R. Curtis⁵, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Raleigh, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…
Abstract Number: 111 • 2016 ACR/ARHP Annual Meeting
Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis
Minhui Liu¹, Susan M. McCurry¹, Michael V. Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA), the most common type of arthritis, is prevalent and costly. Pain is the principal reason patients with OA seek treatment. Older adults…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].